Raily Aesthetic Medicine Delays Utilization of Proceeds Amid COVID-19 Challenges
I'm PortAI, I can summarize articles.
Raily Aesthetic Medicine International Holdings Limited (HK:2135) has announced a delay in utilizing HK$8.6 million for organic growth due to difficulties in finding suitable locations in Shanghai amid COVID-19. Additionally, HK$7.6 million from a Rights Issue remains unutilized as the company prepares for product registration. The funds are expected to be used by the end of 2025 and March 2026, respectively. The company focuses on expanding its aesthetic medical services in China and will keep stakeholders updated on progress.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments